Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Replimune Group Inc REPL

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV... see more

Current News (NDAQ:REPL)

Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL), Sable Offshore Corp. (SOC), Sarepta Therapeutics, Inc. (SRPT), and Semler Scientific, Inc. (SMLR)

GlobeNewswire 11 days ago

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire 13 days ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Replimune Group, Inc. (REPL), and Fly-E Group, Inc. (FLYE)

GlobeNewswire January 20, 2026

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 18, 2025

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

GlobeNewswire November 7, 2025

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire November 6, 2025

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

GlobeNewswire October 20, 2025

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

GlobeNewswire October 19, 2025

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

GlobeNewswire October 8, 2025

Bullboard Posts (NDAQ:REPL)

Using technical analysis for this stock.

It is starting to climb up again from its low prices per share and it's looking really good 
coolfooldumbguy - September 23, 2025

Sell buddy sell.

Otherwise you guys out there will be losing your shorts with this stock today anyway
coolfooldumbguy - September 18, 2025

How does this compare to HOTH?

How would this rate with a smaller company like HOTH?
7Twiggy - July 30, 2025

Buy buddy buy because it's taking off this morning.

Otherwise FOMO for you fellas out there today anyway
coolfooldumbguy - July 30, 2025

Sell buddy sell.

Otherwise you guys out there will be losing your money big time with this stock today
coolfooldumbguy - July 22, 2025

This is a good company

This stock is for a buy and hold in your portfolio.
coolfooldumbguy - January 21, 2025

Podcasts